A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
← catalyst calendarNCT07456774 · readout in 12 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
100,000estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-13 | actual | When the study began enrolling |
| Primary completion | 2026-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Primary outcomes
what the primary-completion date above is the date OFTime to 3P major adverse cardiovascular events
measured From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)
Time to 5P MACE
measured From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)
Time to stroke
measured From index date to the first stroke event or censoring event (up to 36 months)
Time to myocardial infarction (MI)
measured From index date to the first MI event or censoring event (up to 36 months)
Time to heart failure (HF)
measured From index date to the first HF event or censoring event (up to 36 months)
Time to composite renal event
measured From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)
Time to renal disease-related hospitalization
measured From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)
Incidence rate of 3P MACE
measured From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)
Incidence rate of 5P MACE
measured From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)
Incidence rate of stroke
measured From index date to the first stroke event or censoring event (up to 36 months)
Incidence rate of myocardial infarction
measured From index date to the first MI event or censoring event (up to 36 months)
Incidence rate of heart failure
measured From index date to the first HF event or censoring event (up to 36 months)
Incidence rate of composite renal event
measured From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)
Incidence rate of renal disease-related hospitalization
measured From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed